Bicarbonate v Saline to Prevent Contrast Nephropathy
Primary Purpose
Kidney Failure, Acute, Contrast Media
Status
Terminated
Phase
Phase 4
Locations
Italy
Study Type
Interventional
Intervention
0.9% (154 mEq/L) IV Sodium Chloride
1/6 M (166 mEq/L) IV Sodium Bicarbonate
Sponsored by
About this trial
This is an interventional prevention trial for Kidney Failure, Acute focused on measuring Contrast Induced Nephropathy, Chronic Kidney Disease, Acute Renal Failure, End-stage Renal Disease, Cardiovascular diseases, Coronary catheterization, Percutaneous coronary intervention, Intra-arterial angiography, Bicarbonate, Saline
Eligibility Criteria
Inclusion Criteria:
- Booked for cardiac or other non-renal arteriography
- Pre-existing reduced kidney function: Serum Creatinine >= 1.3 & <= 4 mg/dl (female gender) or >= 1.5 & <= 5 mg/dl (male gender)
- Age > 18 years
Exclusion Criteria:
- GFR MDRD estimate < 15 ml/min/m2
- End-stage renal disease already on dialysis
- Known current Acute Kidney Failure with serum creatinine rise of > 0.5 mg/dl within 24 hours
- Pulmonary edema - current or within 48 hours
- Clinically relevant ascites, edema or other fluid overload
- Uncontrolled hypertension (> 165 mmHg systolic, or > 105 mmHg diastolic)
- Hemodynamically unstable patient requiring IV nitroglycerine, or IV fluid or inotropes for blood pressure support
- Emergency (unplanned) angiography
- IV contrast procedure
- Exposure to iodinated radiocontrast within 3 days prior to study
- Prior anaphylactoid reaction to contrast
- Planned administration of N-acetylcysteine
- Planned administration of dopamine, fenoldopam or mannitol
- Current pregnancy
Sites / Locations
- Spedali Civili di Brescia
- Ospedale Ferrarotto
- P.O. Uboldo
- Azienda Istituti Ospitalieri di Cremona
- IRCCS Policlinico San Donato
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Bicarbonate
Saline
Arm Description
Bicarbonate solution infusion
Standard volume expansion
Outcomes
Primary Outcome Measures
Development of contrast-induced nephropathy, CIN, defined as an increase in serum creatinine of 25% or more from pre-intervention baseline to within 48-72 hours after administration of the radiographic contrast.
Secondary Outcome Measures
Group mean change in serum creatinine
Days in hospital within the week post contrast
Requirement for dialysis
Atheroembolic events
Major adverse cardiovascular events
Death
Full Information
NCT ID
NCT00384995
First Posted
October 5, 2006
Last Updated
November 29, 2010
Sponsor
Italian Society of Nephrology
Collaborators
European Commission, Memorial University of Newfoundland
1. Study Identification
Unique Protocol Identification Number
NCT00384995
Brief Title
Bicarbonate v Saline to Prevent Contrast Nephropathy
Official Title
Phase 4 Study of Bicarbonate Versus Saline Infusion Therapy to Prevent Contrast Induced Nephropathy (CAN-IT PREVENT Protocol)
Study Type
Interventional
2. Study Status
Record Verification Date
November 2010
Overall Recruitment Status
Terminated
Why Stopped
Lack of funding
Study Start Date
December 2006 (undefined)
Primary Completion Date
July 2009 (Actual)
Study Completion Date
July 2009 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Italian Society of Nephrology
Collaborators
European Commission, Memorial University of Newfoundland
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Slowing of kidney function occurs in a minority of people given dye during angiography. The purpose of this study is to compare two different types of fluid given into a vein to reduce the risk of kidney injury: salt in water or baking soda in water.
Detailed Description
A decline in kidney function after contrast is associated with prolonged hospital stay, adverse cardiac events, and higher mortality both in hospital and in the long term. Deliberate administration of fluids is recommended to reduce the risk of contrast nephropathy. However, data to support specific recommendations are lacking and the optimal fluid regimen remains unclear.
It has been hypothesized that alkalinization of tubular fluid might be beneficial by reducing pH dependent free radical levels. A recent trial found a lower frequency of creatinine rise > 25% within two days of contrast with a 7 hour infusion of isotonic sodium bicarbonate than with saline infusion (Merten GJ, JAMA 2004). However, it remains to be proven that bicarbonate is superior as this trial has a number of methodological flaws.
Comparison: IV 1/6 M sodium bicarbonate OR IV 0.9% saline, each isotonic fluid given at the same rate of sodium administration (3.25 ml/Kg over 1 hour pre-contrast, followed by 1.1 ml/Kg/hr for 6 hours for bicarbonate; 3.5 ml/Kg over 1 hour pre-contrast, followed by 1.2 ml/Kg/hr for 6 hours for saline). Total infusion time 7 hours (for both). Maximum rate of fluid permitted is that for a body weight of 110 Kg. Intra-vascular iso- or low-osmolality contrast in the minimal dose needed to complete the required imaging.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Kidney Failure, Acute, Contrast Media
Keywords
Contrast Induced Nephropathy, Chronic Kidney Disease, Acute Renal Failure, End-stage Renal Disease, Cardiovascular diseases, Coronary catheterization, Percutaneous coronary intervention, Intra-arterial angiography, Bicarbonate, Saline
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
61 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Bicarbonate
Arm Type
Experimental
Arm Description
Bicarbonate solution infusion
Arm Title
Saline
Arm Type
Active Comparator
Arm Description
Standard volume expansion
Intervention Type
Drug
Intervention Name(s)
0.9% (154 mEq/L) IV Sodium Chloride
Other Intervention Name(s)
Sodium Chloride
Intervention Description
Saline solution
Intervention Type
Drug
Intervention Name(s)
1/6 M (166 mEq/L) IV Sodium Bicarbonate
Other Intervention Name(s)
Sodium Bicarbonate
Intervention Description
Bicarbonate solution
Primary Outcome Measure Information:
Title
Development of contrast-induced nephropathy, CIN, defined as an increase in serum creatinine of 25% or more from pre-intervention baseline to within 48-72 hours after administration of the radiographic contrast.
Time Frame
48-72 hours
Secondary Outcome Measure Information:
Title
Group mean change in serum creatinine
Time Frame
48-72 hours
Title
Days in hospital within the week post contrast
Time Frame
One week
Title
Requirement for dialysis
Time Frame
Two months
Title
Atheroembolic events
Time Frame
Two months
Title
Major adverse cardiovascular events
Time Frame
Two months
Title
Death
Time Frame
Two months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Booked for cardiac or other non-renal arteriography
Pre-existing reduced kidney function: Serum Creatinine >= 1.3 & <= 4 mg/dl (female gender) or >= 1.5 & <= 5 mg/dl (male gender)
Age > 18 years
Exclusion Criteria:
GFR MDRD estimate < 15 ml/min/m2
End-stage renal disease already on dialysis
Known current Acute Kidney Failure with serum creatinine rise of > 0.5 mg/dl within 24 hours
Pulmonary edema - current or within 48 hours
Clinically relevant ascites, edema or other fluid overload
Uncontrolled hypertension (> 165 mmHg systolic, or > 105 mmHg diastolic)
Hemodynamically unstable patient requiring IV nitroglycerine, or IV fluid or inotropes for blood pressure support
Emergency (unplanned) angiography
IV contrast procedure
Exposure to iodinated radiocontrast within 3 days prior to study
Prior anaphylactoid reaction to contrast
Planned administration of N-acetylcysteine
Planned administration of dopamine, fenoldopam or mannitol
Current pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pietro Ravani, MD, MSc
Organizational Affiliation
Italian Society of Nephrology
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Brendan BJ Barrett, MD, MSc
Organizational Affiliation
Memorial University of Newfoundland
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Ferruccio Conte, MD
Organizational Affiliation
Italian Society of Nephrology
Official's Role
Study Chair
Facility Information:
Facility Name
Spedali Civili di Brescia
City
Brescia
ZIP/Postal Code
25100
Country
Italy
Facility Name
Ospedale Ferrarotto
City
Catania
ZIP/Postal Code
95100
Country
Italy
Facility Name
P.O. Uboldo
City
Cernusco sul Naviglio
ZIP/Postal Code
20063
Country
Italy
Facility Name
Azienda Istituti Ospitalieri di Cremona
City
Cremona
ZIP/Postal Code
26100
Country
Italy
Facility Name
IRCCS Policlinico San Donato
City
San Donato
ZIP/Postal Code
20097
Country
Italy
12. IPD Sharing Statement
Citations:
PubMed Identifier
15150204
Citation
Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, Bersin RM, Van Moore A, Simonton CA 3rd, Rittase RA, Norton HJ, Kennedy TP. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004 May 19;291(19):2328-34. doi: 10.1001/jama.291.19.2328.
Results Reference
background
PubMed Identifier
17943084
Citation
Ravani P, Tripepi G, Pecchini P, Mallamaci F, Malberti F, Zoccali C. Urotensin II is an inverse predictor of death and fatal cardiovascular events in chronic kidney disease. Kidney Int. 2008 Jan;73(1):95-101. doi: 10.1038/sj.ki.5002565. Epub 2007 Oct 17.
Results Reference
derived
Learn more about this trial
Bicarbonate v Saline to Prevent Contrast Nephropathy
We'll reach out to this number within 24 hrs